LOS ANGELES, March 7 (Reuters) - Keryx Biopharmaceuticals Inc (KERX.O) said on Friday that a Phase 3 clinical trial for Sulonex, a drug designed to treat diabetic neuropathy, has failed to meet the study's primary objectives.
The company said it plans to re-focus its primary efforts and resources on rapidly moving renal disease drug Zerenex and cancer drug Perifosine forward. (Reporting by Gina Keating; editing by Carol Bishopric)
KABUL (Reuters) - Insurgents intensified their campaign against military targets and U.S.-led forces in Afghanistan, killing eight U.S. CIA agents at a base and four Canadian servicemen on patrol and a journalist accompanying them.
Critics say the Sept. 11 trials will endanger America's most populated city. Will a New Year's Eve plan hold up as New York's security template? Full Article
Boycotting "too big to fail" banks is a great idea -- so long as investors remember that banks aren't the only ones responsible for the crisis. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
